It has been suggested that the immunological properties of cytokine primed PBSC may reflect the presence of altered levels of cellular components. In this study the changes induced in blood dendritic cell (DC) subsets following G-CSF mobilisation are analysed. Analysis of normal donors (n = 64) demonstrated considerable individual variation in the absolute numbers (؋10 6 /l) of resting blood CD11c ؊ DC (1.2-26.2) and CD11c + DC (0.9-34.7) as well as in the CD11c ؊ /CD11c + DC ratio (0.
dence of acute GVHD than bone marrow grafts, [2] [3] [4] despite at least a 10-fold higher T cell dose, 5 and they achieve better engraftment across HLA barriers. 6, 7 In vitro human studies have demonstrated that PBSC products have high levels of T cell inhibitory activity. [8] [9] [10] [11] [12] [13] This effect has been variously attributed to the high levels of IL-10 produced by monocytes, 14 to modulation of monocyte function, 15 and more recently, to a mobilisation-associated increase in certain dendritic cell (DC) subsets. 16, 17 DC constitute a system of antigen-presenting cells that play a critical role in regulating immune responses. 18 Although DC have historically been considered as inducers of immune responses, it has become clear that they also play a critical role in the induction of tolerance/ suppression 18 and have also been shown to have anti-cancer cytotoxic activity. 19 The role and potential therapeutic use of DC in modulating immune function is therefore of considerable interest in the fields of transplantation and cancer immunotherapy. 20, 21 DC populations are morphologically and phenotypically heterogeneous and in humans two phenotypically distinct subsets of blood DC have been identified based on their differential expression of CD11c and CD123 (CD11c + , CD123 dim 'myeloid' DC and CD11c Ϫ , CD123 + 'lymphoid' DC). [22] [23] [24] Although these two blood DC subsets appear to represent different DC lineages, it is presently unclear whether they also have distinct functional roles, particularly with respect to their relative abilities to induce tolerance and/or changes in the Th1/Th2 balance. 25 The enumeration of these subsets is therefore of considerable interest, as it may provide information relevant not only to determining the functional differences between these subsets but also to their possible role in disease processes and therapeutic strategies. In particular it is important to determine whether cytokines used clinically elicit the expansion of functionally distinct DC subsets. In this regard, it has been reported that G-CSF treatment preferentially induces a significant increase in the number of CD11c Ϫ blood DC. 16, 17 A number of studies have reported values for the total number of circulating DC in normal blood, although the majority of these studies analysed only a small number of donors, or enumerated activated DCs after in vitro culture. [26] [27] [28] [29] Studies on the enumeration of the blood DC subsets have been more limited, and have analysed either only Bone Marrow Transplantation a small number of samples, or quantified only a single subset. 16, 17, 24, [30] [31] [32] Although it has been reported that, overall, the mean number of CD11c + DC is slightly higher than the mean number of CD11c Ϫ DC, these results were obtained from small numbers of donors and the ratio of these subsets in individual donors has not been reported.
It is clear from analysis of normal allogeneic donors as a group that G-CSF treatment increases CD11c
Ϫ DC numbers, 16 ,17 but it has not been reported whether this is the case in all individuals, or whether the observed increase results from changes in only a subset of donors. It is also unclear whether the post-mobilisation CD11c Ϫ /CD11c + DC ratio is altered in all individuals, and whether these ratios fall outside of the values observed in normal unmobilised donors. The effect of G-CSF mobilisation on DC subsets in patients undergoing harvests for autologous transplantation is also presently unknown.
In this study we have utilised a method with minimal manipulation to establish the normal range for absolute number and ratio of the CD11c + and CD11c Ϫ DC subsets in a large number of normal individuals. We also report the changes in the absolute number and ratio of the DC subsets following G-CSF mobilisation in normal allogeneic donors and patients undergoing mobilisation for autologous transplantation.
Materials and methods

Normal peripheral blood samples
A total of 64 peripheral blood (PB) samples from healthy adult subjects were analysed in this study. The mean age of these individuals was 36 Ϯ 2 years (range 20-63 years: median 33 years); the ratio of male/female was 28:36, respectively. All samples were obtained with informed consent and the approval of the local Ethics Committee. PB samples (approximately 5 ml) were collected in EDTA anticoagulant and processed on the day of collection.
G-CSF mobilisation samples
Samples from patients undergoing autologous or allogeneic stem cell G-CSF mobilisation were obtained with informed consent. Normal donors received G-CSF doses of 5-10 g/kg/day for 4 or 5 days. Patients undergoing autologous PBSCT received varying regimens (Table 1 ). Blood samples (5 ml) were collected into EDTA immediately prior to the first G-CSF (G-CSF; Roche, Auckland, New Zealand) administration and again immediately prior to leukapheresis collection of the harvest product. Harvests from mobilised patients were usually initiated on the day that the CD34 + count was greater than or equal to 20 ϫ 10 6 /l (day 4 or 5 post G-CSF). However, in three patients CD34 levels were lower than 20 ϫ 10 6 /l at the time of harvest. A sample from the harvest product was also obtained. The number of WBC was determined using a Coulter STKS (Coulter Electronics, Hialeah, FL, USA).
Monoclonal antibodies
Purified mAbs used in this study were: CD3-PE (Leu-4), CD14-PE (Leu-M3), CD19-PE (SJ25C1), CD20-PE (Leu-16), CD56-PE (Leu-19), CD34-PE (Anti-HPCA-2), IgG1-PE, (Becton Dickinson, San Jose, CA, USA); CD16-PE (DJ130c), CD11c-FITC (KB90) (DAKO, Glostrup, Denmark); HLA-DR-PC5 (IMMU357) CD83-FITC (HB15), (Beckman Coulter, Marseille, France), CD86-FITC (BD-PharMingen, San Diego, CA, USA).
Flow cytometric enumeration of DC
Whole blood samples were stained without further separation to minimise possible selective loss of leukocyte subsets. For enumeration of DC subsets blood samples (100 l/test) were simultaneously incubated (20 min, RT, in the dark) with anti-HLA-DR-PC5, CD11c-FITC and a cocktail of PE-conjugated mAbs (MIX-PE) specific for the progenitor cell marker CD34 and the lineage markers CD3, CD14, CD16, CD19, CD20 CD56. DC expression of CD86 and CD83 was analysed by labelling of additional samples with either CD83-FITC or CD86-FITC in combination with anti-HLA-DR-PC5 and MIX-PE. Following labelling red cells were lysed by addition of 2 ml of lysing buffer (10 mm NH 4 HCO 3 , 144 mm NH 4 Cl, 10 mm KCl, 0.1 mm EDTA pH 7.2) and further incubation (10 min, RT). Cells were then washed in PBS and analysed on a FACS Vantage flow cytometer using Cellquest software (Becton Dickinson).
Live cells were gated on the basis of forward and side light scatter characteristics (Figure 1a ). Live cells that did not label with PE-conjugated CD34 and lineage-specific mAb were designated as lin Ϫ (Figure 1b ) and following gating on lin Ϫ WBC the percentages of total DC and DC subsets present was analysed in plots of CD11c vs DR (Figure 1c ). The total DC population was identified as lin Ϫ , DR + WBC and within this population CD11c expression was used to determine the proportion of each DC subset. Duplicate tubes were analysed for each sample and following subtraction of negative control staining the mean of these values was used to determine DC percentage. Multiplication of the WBC count by the DC percentages was used to calculate the absolute number of DC in the sample.
Flow cytometric analysis of CD34 numbers
CD34 numbers were enumerated according to the ISHAGE protocol 33 and analysed on a Beckman Coulter, Epics XL flow cytometer.
Statistical analysis
Because of the skewed distribution of some of the data nonparametric tests were used throughout. Differences between unpaired groups were evaluated by the Mann-Whitney U test and the differences between paired groups evaluated by the Wilcoxon matched pairs test. Correlations were determined with Spearmans rank correlation. P values Ͻ0.05 were considered significant. 
Results
Identification and enumeration of DC subsets
The total DC population and the CD11c Ϫ and CD11c + DC subsets within individual blood samples were enumerated by triple colour labelling in combination with flow cytometric analysis (Figure 1 ). The mean absolute number of total DC (lin Ϫ DR + ) in the 64 normals analysed was 17.9 ϫ 10 6 /l blood (95% CI = 15.2-20.6), and the observed range was 2.5 to 49.9 ϫ 10 6 /l, (Figure 2a ). The overall frequency of DC in normal donors was 0.75% of all mononuclear cells (range 0.10-1.87%). Analysis of the CD11c
Ϫ and CD11c
+ DC subpopulations demonstrated that both subsets had a similar range of concentrations in blood although, overall the mean absolute number of CD11c + DC (9.6 ϫ 10 6 /l, range 0.9-34.7) was slightly higher than that of the CD11c Ϫ DC (8. Figure 2 Absolute numbers of blood DC. Blood from (a) normal donors, (b) G-CSF-mobilised normal donors and (c) G-CSF-mobilised patients was analysed as described in Methods, and total DC, CD11c Ϫ DC and CD11c + DC numbers expressed as absolute counts (ϫ10 6 /l). Blood samples were collected from all mobilised individuals both pre-(b) and post (᭺) mobilisation. Data are shown as scatterplots and the median value for total DC and DC subset numbers is shown as a solid line. absolute DC or DC subset number independently correlated with age or sex.
Analysis of G-CSF mobilised normal allogeneic donors
The effect of G-CSF therapy on blood leukocyte populations was studied in six normal donors who were analysed pre-and post-mobilisation.
Mobilisation resulted in a dramatic increase in the WBC count (five-to 11-fold) of all six normal donors and this increase was associated with a similar rise (five-to 16-fold) in neutrophil numbers (Table 1 , data not shown). Increases in monocyte and lymphocyte numbers were also observed in all donors although these increases were of smaller magnitude and similar to the increases (0.8-to 4.7-fold) observed in total DC number ( Figure 2b , Table 1 ).
Mobilisation resulted in an increase in total DC number in 4/5 donors although this increase was, overall, not statistically significant (Figure 2b) . Analysis of the changes in DC subsets demonstrated that mobilisation resulted in a significant increase in the absolute numbers of CD11c Ϫ DC (P = 0.03) while only a small, unsignificant change in the number of CD11c + DC (P = 0.34) was observed ( Figure  2b , Table 1 ). In all mobilised donors the number of CD11c Ϫ DC was higher than the normal range while in four of the mobilised donors the total DC number was also higher than the normal range. These changes in DC subset numbers resulted in a significant overall increase in the CD11c Ϫ /CD11c + ratio (P = 0.03) which, in all cases, was у2.0 (Figure 3b) . However, only one of the donors had a CD11c Ϫ /CD11c + ratio that was higher than the normal range.
The relative change, as a fold increase, in total DC and DC subset numbers following mobilisation was calculated for each individual donor (Figure 4a ). In five of the six donors there was a у1.5-fold increase in the absolute number of both total DC and CD11c
Ϫ DC following mobilisation. Only small changes in the number of CD11c + DC were observed. In contrast, mobilisation of one of the six donors (No. 03) resulted in a small decrease in total DC number, a small increase in CD11c Ϫ number and a large (Ͼ4-fold) decrease in the CD11c + DC number. Nonetheless, mobilisation resulted in an increase (1.4-to 5.6-fold) in the CD11c Ϫ /CD11c + ratio in all six donors and in five of them there was Ͼ2-fold increase ( Table 1) .
The mobilised donors had both a significantly higher CD11c Ϫ /CD11c + ratio (P = 0.0007) and significantly higher numbers of total DC (P = 0.002), CD11c
Ϫ DC (P Ͻ 0.0001) and CD11c
+ DC compared to normal donors (P = 0.044). With respect to both absolute numbers and fold increases there was no apparent correlation between the DC subsets and total WBC, neutrophils, lymphocytes or monocytes. Similarly, there was no correlation between CD34 numbers and the number of total DC, DC subsets or WBC ( Table 1) 
. Comparison of the CD11c
Ϫ /CD11c + DC ratio in mobilised blood vs the apheresis product demonstrated that apheresis did not significantly (P = 0.68) alter these ratios (data not shown).
Analysis of G-CSF-mobilised patients
The effect of G-CSF treatment was also studied in 14 patients undergoing mobilisation for autologous transplantation. The total WCC (Table 1) , neutrophil, monocyte and lymphocyte counts (data not shown) of all patients were within the normal range prior to mobilisation. The total DC number in the majority of patients was also within the normal range prior to treatment, although five of the patients had levels at the lower end of the normal range and two patients (patients 1 and 7) had DC numbers that were considerably higher than those observed in normal individuals (Figure 2c) .
The G-CSF-induced changes in the leukocyte populations of these patients were considerably more heterogeneous than those observed in mobilised normal donors (Table 1) , and this may reflect the fact that the mobilisation regimen in most patients included chemotherapy. Although all normal donors had WCC counts Ͼ30 ϫ 10 9 /l following mobilisation, the majority (9/14) of mobilised patients had WCC counts р12 ϫ 10 9 /l. In six of the patients mobilisation resulted in a decrease in the total WBC count, although the total DC number decreased in only four of this group (Table 1) .
Although there was considerable variation in individual patient responses to mobilisation there was overall a small increase in mean values for total DC and DC subset numbers (Figure 2c ). However, in contrast to G-CSF-treated normal donors, the majority of mobilised patients had total DC and CD11c Ϫ DC numbers that fell within the normal range. Mobilisation did not significantly alter CD11c + DC numbers in the majority of patients, although two patients (Nos 5 and 12) had numbers higher than the normal range. Interestingly, the two patients with elevated DC numbers pre-mobilisation only had normal levels of each subset following mobilisation.
The CD11c Ϫ /CD11c + ratio of patients was, overall, not significantly altered during mobilisation (Figure 3c ). The relative change in total DC and DC subsets following mobilisation was calculated for each individual patient (Figure 4c ). In eight of the 14 patients there was an increase in the absolute number of both total DC and CD11c Ϫ DC following mobilisation. In five of those eight patients there was also a greater than three-fold increase in CD11c + DC which, in four of them, was greater than nine-fold. In contrast, the remaining nine patients had CD11c + DC numbers that remained unchanged or decreased following mobilisation. Determination of the mobilisation-induced changes in CD11c Ϫ /CD11c + DC ratios demonstrated that in five of the 14 patients the ratio was decreased. Although an increase was observed in nine of the patients this increase was greater than two-fold in only three.
The mobilised patients had both significantly higher
Bone Marrow Transplantation numbers of total DC (P = 0.04) and CD11c Ϫ DC (P = 0.01), and a significantly higher CD11c Ϫ /CD11c + ratio when compared to normal donors (0.0275). Numbers of CD11c + DC were not significantly different from normal donors (P = 0.2)
There was no apparent correlation between postmobilisation DC numbers and either CD34 + or WBC count.
Effect of mobilisation on CD86 and CD83 expression
The upregulation of CD86 and CD83 expression is an early event in DC activation. Expression of these antigens was analysed in all normal donors (n = 6) and the majority (10/14) of patients both pre-and post mobilisation. In all individuals analysed no detectable expression of CD83 by the DC populations was observed either pre-or post mobilisation (data not shown). In 15 of the 16 individuals analysed only weak expression of CD86 was observed and this was limited to a subpopulation of the DC present. Mobilisation did not increase DC expression of CD86 in these individuals (Figure 5a ), although both CD83 and CD86 were upregulated after overnight culture, as is seen in DC from normal individuals (data not shown). In contrast, the DC from one patient with CML showed elevated expression of CD86 prior to mobilisation and this expression was increased further by mobilisation (Figure 5b ). The harvest products from 10 individuals were also analysed and demonstrated that the leukapheresis procedure itself did not alter DC expression of either CD83 or CD86 (data not shown).
Discussion
The importance of DC in the initiation of primary immune responses is well established, and in the field of transplantation led to the concept that DC elimination would lead to graft acceptance. More recent studies, however, suggest that DC also play an important role, not only in the induction of tolerance, but also as cytotoxic anticancer cells. 19, 20 Initial studies suggested these differing functional roles were carried out by distinct DC subsets such as the CD11c + and CD11c
Ϫ blood DC identified in humans. 34 However, more recent data have demonstrated that these subsets do in fact have considerable functional plasticity 25, 35, 36 and their functional and clinical significance therefore remains unclear.
Recent interest on the role of these different subsets in transplantation has focused on the possibility that G-CSF mobilisation induces changes in blood CD11c
+ and CD11c
Ϫ DC subsets that subsequently influences the function of PBSC grafts. 16, 17, 37 In order to fully evaluate the effect of G-CSF on blood DC subsets it is necessary to establish a baseline normal range for both the absolute number and ratio of these subsets. The majority of previous studies have analysed only small numbers of donors or enumerated only a single subset. 16, 17, 24, [30] [31] [32] Our analysis of a large number of normal donors provided results for the absolute number of each subset that are in line with the results of those previous studies and emphasise the large individual variation in both the total DC and DC subset number. In accordance with previous reports we also found that when normal donors were analysed as a group the mean number of CD11c + DC was slightly higher than the CD11c Ϫ DC. The normal range for individual CD11c Ϫ /CD11c + ratios has not been previously reported and the results of this study clearly demonstrate that there is in fact considerable individual variation in this ratio. In a significant proportion of donors (29%) there was a greater than two-fold difference in the numbers of circulating CD11c
Ϫ and CD11c + DC. This finding, together with the large variation in individual DC numbers observed, has considerable implications with respect to the interpretation of DC enumeration data. Many studies evaluate the significance of patient DC numbers either by comparison with the data from a small number of normal donors or by comparison of the mean values from patients and normals. It is clear from this study, however, that, because of the wide range of normal values, the effect of a disease/treatment on DC subsets can only be effectively determined by comparing pre-and post disease/treatment blood samples, or by comparing results to a normal range established from a large number of donors.
In this study the effect of G-CSF mobilisation on individual normal donors was analysed and revealed a consistent pattern of response with respect to the DC subsets. In all normal donors there was a significant increase in the CD11c Ϫ DC subset and this together with the relatively small changes in CD11c + DC numbers resulted in a substantial increase in the CD11c Ϫ /CD11c + ratio. The effect of G-CSF mobilisation on DC subsets in patients undergoing autologous PBSCT has not been previously reported. The response of individual patients to mobilisation was considerably more heterogeneous than that observed in normal donors and no consistent pattern was observed with respect to the changes induced in either DC or non-DC populations. This heterogeneity in response may reflect the differing conditioning regimens that the patients received prior to mobilisation, although analysis of a larger patient group would be required to determine whether this is the case. In contrast to normal donors, the number of CD11c
Ϫ DC actually decreased in many of the patients following mobilisation, and only a minority had CD11c Ϫ DC numbers higher than the normal range. The changes in patient CD11c
+ subset numbers also contrasted with the pattern observed in normal donors with numbers increasing in a number of patients and 2/14 patients having numbers higher than the normal range. A potential problem in the enumeration of DC in patients with malignancies is that the malignant population may have a DC-like phenotype (ie lin Ϫ DR + ) and if so their presence may inflate the number of DC detected using our enumeration method.
Phenotypic data demonstrating that the malignant population did not have a lin Ϫ DR + phenotype was available from only six of the 14 patients studied. The possibility that a number of the eight remaining patients had circulating lin Ϫ DR + malignant cells could not be excluded. However this would have the effect of increasing DC numbers, and in most patients the total DC or CD11c
Ϫ DC numbers detected were not above the normal range. It could provide a possible explanation for the detection of high levels of CD11c + DC in two patients following mobilisation, but this seems unlikely as one of these patients (No. 12) was in cytogenetic remission at the time of analysis.
These results suggest that in patients either the malignancies, and/or prior clinical treatments, substantially alter the effect G-CSF has on the expansion of DC subsets. In terms of both the absolute number and ratio of DC subsets, PBSC products from mobilised patients have little similarity to those obtained from mobilised normal donors.
The CD11c Ϫ and CD11c + DC subsets are thought to arise from the lymphoid and myeloid lineages respectively. 18, 25 Although the concept that these subsets are also functionally distinct is attractive, current evidence suggests that they do not differ intrinsically in their capacity to stimulate Th1 vs Th2 responses. 25 It appears that both capacities can be acquired by uncommitted immature DC of either lineage, and is dependent on the type and kinetics of the signals delivered by the local microenvironment. 25, 35, 36 The different DC subsets do, however, differ in their expression pattern of receptors and so may differ primarily in their ability to recognise different antigens. 25 The ability of DC to induce either immunity or tolerance following antigen uptake has also been linked to their state of activation/maturation. 18, 25 Our finding that mobilised DC lack significant expression of the early DC activation antigens CD83 and CD86 is consistent with two previous reports 16, 17 and suggests that the mobilised DC remain in an immature state. The immunosuppressive properties of PBSC grafts may therefore arise from the presence of elevated numbers of immature DC rather than from an increase in one particular DC subset. It has been recently reported that immature but not mature DC are able to directly mediate anti-cancer activity. 19 The presence of elevated numbers of immature DC in PBSC grafts may therefore also have a direct effect on the malignant population.
Analysis of a larger patient group is needed to determine if there is any correlation between PBSC DC content and clinical outcomes such as the onset/severity of GVHD and relapse.
